Accelerating the Development of Life Transforming Medicines which have the Potential to Generate Significant Value



★ Orphan drug designations in at least one indication

● US Breakthrough and/or EU PRIME designations in at least one indication

● Japan SAKIGAKE and/or China Breakthrough designations in at least one indication

Late-stage program: Program in or expected to be in potential pivotal trial or having achieved proof-of-concept.

Approved

Target Filing, anticipated year of filing for regulatory approval

Targeted pivotal study / Phase 3 start

Proof-of-concept/Dose ranging Phase 2 study readout

Phase 2 study start

Accelerated from previously assumed timeline

All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Maximizing Potential of Marketed Portfolio Through LCM Expansions



1. Submission based on data from German Hodgkin Study Group HD21 trial. Positive CHMP opinion.
2. HyHub: Advanced vial access for a sterile, single-use medical device that significantly simplifies the preparation and delivery of fSCIG from vials
3. QDENGA approved in Vietnam (May 2024), Israel (May 2024), Switzerland (July 2024)

All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Glossary of Abbreviations

Regional Abbreviations:
CN: China; EU: Europe; JP: Japan; U.S.: United States of America

AA	anemia-associated
AATD	α1-antitrypsin deficiency
AATD LD	α1-antitrypsin deficiency associated liver disease
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADC	antibody–drug conjugate
AE	adverse event
ALGS	Alagille syndrome
ASCO	American Society of Clinical Oncology
ASH	American Society of Hematology
ASN	American Society of Nephrology
AVA	Advanced Vial Access
BID	bis in die, twice a day
BTD	breakthrough therapy designation
CAR NK	chimeric antigen receptor natural killer cell
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CML	chronic myeloid leukemia
CMV	cytomegalovirus
CP-CML	chronic-phase chronic myeloid leukemia
CRC	colorectal cancer
CRPC	castrate-resistant prostate cancer
cTTP	congenital thrombotic thrombocytopenic purpura
DOAC	direct oral anti-coagulation
DS	Dravet syndrome
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
FDA	U.S. Food & Drug Administration
FL	front line
fSCIG	facilitated Subcutaneous Immunoglobulin
FY	fiscal year
GI	gastrointestinal
GvHD	graft versus host disease
H2H	head-to-head
HAE	hereditary angioedema
HCP	healthcare professional
HemA	hemophilia A
HL	Hodgkin lymphoma
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
IgG	immunoglobulin G
IH	idiopathic hypersomnia
IND	investigational new drug
INN	international non-proprietary name
ISTH	International Society on Thrombosis and Haemostasis
ITP	immune thrombocytopenia
iTTP	immune thrombotic thrombocytopenic purpura
IV	intravenous
JAK	Janus kinase
LCM	lifecycle management
LGS	Lennox-Gastaut syndrome
mCRC	metastatic colorectal cancer
MDD	major depressive disorder
MDS	myelodysplastic syndrome
MF	myelofibrosis
MFSAF	Myelofibrosis Symptom Assessment Form
MMN	multifocal motor neuropathy
MSA	multiple system atrophy
NDA	new drug application
NK	natural killer
NME	new molecular entity
NMPA	(China's) National Medical Products Administration
NT1 or 2	narcolepsy type 1 or 2
OX2R	orexin 2 receptor
PDT	plasma derived therapies
PFIC	progressive familial intrahepatic cholestasis
Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
PID	primary immunodeficiency
PK	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept
PRIME	Priority medicines scheme by EMA
PROC	platinum-resistant ovarian cancer
PROMIS	Patient-Reported Outcomes Measurement Information System
PsO	psoriasis
PSOC	platinum-sensitive ovarian cancer
PTRS	probability of technical and regultory success
PV	polycythemia vera
QD	quaque die, every day
QOL	quality of life
RTU	ready to use
SAE	serious adverse event
SC	subcutaneous formulation
SID	secondary immunodeficiency
SOC	standard of care
TKI	tyrosine kinase inhibitor
TYK2	tyrosine kinase 2
UC	ulcerative colitis
vWD	von Willebrand disease
wk(s)	week(s)
WW	worldwide